Notably, the majority of mechanistic data supporting this concentration-dependent model derives from preclinical studies using mouse pancreatic -cells and clonal cell lines, with limited validation in human islet studies, necessitating further clinical investigation to confirm these concentration thresholds in human diabetes treatment [23,24,25,26]
Unlike traditional GLP-1 drugs, FOUNDAYO is a non-peptide small molecule designed to activate the GLP-1 receptor
For a peptide that targets fat metabolism, this degree of systemic safety is notable
Where We Still Have Questions We dont yet know how GLP-1s might help women with: Autoimmune conditions Unexplained infertility Normal weight but recurrent fertility struggles Its tempting to imagine benefitsespecially from the anti-inflammatory effectsbut right now, the data isnt there
"The Cat's Meat Man: Feeding Felines in Victorian London"